Henan proposes severe and major disease drug reimbursement

Henan province’s Healthcare Security Administration (HHSA) bureau released a notification in relation to severe and major disease drug reimbursement in the outpatient setting. The provincial government makes it clear that drugs involved in the reimbursement drug list (RDL) through national price negotiations will be covered by medical insurance funds under different categories according to use characteristics, use cycle, course expenditure and other factors.

Nationally negotiated drugs for the treatment of cancer, rare diseases and other serious and catastrophic diseases, which are clinically essential, relatively expensive and suitable for outpatient treatment but have proven efficacy and clear indications, will be designated as “outpatient-specific drugs” and managed under one roof. Miglustat and 26 other drugs that went through national price negotiations in 2019 are tentatively designated as such drugs.

The reimbursement scope and conditions for severe and major disease drugs in Henan province, including trastuzumab and eight others, will be adjusted to match national standards.

For drugs not designated “outpatient-specific drugs”, the coordinated areas may, on the premise of securing medical insurance funds and rational medication, involve those eligible in the medical insurance coordinated funds payment through the outpatient special chronic disease treatment channel, or make use of cost controls such as diagnosis related group (DRG)-style payments.

There is no deductible for those insured in Henan who claim reimbursement for outpatient-specific drug expenses involved in the coordinated basic medical insurance funds. Initial out-of-pocket for Class B outpatient-specific drugs is set at 20% across the province.


Related news
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:600196; HKG:02196) released its Q4 2019 financial report.
US-based employee management and risk consulting specialist Mercer LLC revealed that its health management and welfare team is working with Swiss major Roche’s China unit to innovate new commercial health insurance products.
  • 1585634879967
  • China
  • Deals
GBI analysis shows that Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) last week approved Pint Pharma’s kinase inhibitor Nerlynx (neratinib) and Merck, Sharp & Dohme (MSD)’s reverse transcriptase inhibitor Delstrigo (doravirine + lamivudine + tenofovir disoproxil fumarate).
Swiss major Roche Inc., released its full-year financial results for 2019.
Merck Sharp & Dohme Inc., (MSD; NYSE.MRK) released its Q4 2019 financial report, revealing global revenues growth of 13% year-on-year (YOY) in constant currency terms to USD 46.8 billion for the full-year.
Recent news
GBI recently had the opportunity to talk with Dr. Lu Xianping, the president and co-founder of one of China’s earliest innovation-focused biotechs, Shenzhen Chipscreen Bioscience.
  • 1585728801763
  • China
The outbreak of the novel coronavirus first detected in China in 2019 (2019-nCoV) and its associated disease, COVID-19, has spiralled into a generational healthcare challenge of global scale.
  • 1585728673006
  • China
US-based, China-focused biotech BeyondSpring Inc., (NASDAQ: BYSI) announced the initiation of a rolling New Drug Application (NDA) for plinabulin as a treatment for chemotherapy induced neutropenia (CIN).
  • 1585724852082
  • China
  • Drug
China-based biotech Brii Biosciences has moved in to sign up Tsinghua University and the 3rd People’s Hospital of Shenzhen to a licensing agreement, after researchers at the two institutions identified multiple neutralizing monoclonal antibodies (mAbs) with therapeutic potential against SARS CoV-2 and COVID-19.
China-based Hansoh Pharmaceutical Group Co., Ltd (HKEX.3692) released its Q4 2019 financial report.
China-based internet healthcare provider Ping An Healthcare and Technology Co., Ltd (1833.HK), also known as Ping An Good Doctor, announced that its Internet hospital has been linked with the online Basic Medical Insurance (BMI) scheme settlement system in Hubei province.
Analytics Snapshot

Analytics Snapshot